{
  "analyses": [
    {
      "symbol": "SRRK",
      "approved": true,
      "consensus_score": 7.08,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5.5,
        "risk": 6.5
      },
      "position_size_pct": 3,
      "position_size_shares": 93,
      "current_price": 32.82,
      "stop_price": 27.9,
      "target_price": 45,
      "catalyst": "FDA PDUFA Sept 22 - apitegromab approval"
    },
    {
      "symbol": "INCY",
      "approved": true,
      "consensus_score": 7.88,
      "agent_scores": {
        "fundamental": 8.5,
        "technical": 7.8,
        "news": 9.0,
        "sentiment": 8,
        "bull": 8.8,
        "bear": 5,
        "risk": 8
      },
      "position_size_pct": 5,
      "position_size_shares": 60,
      "current_price": 84.97,
      "stop_price": 81.57,
      "target_price": 92,
      "catalyst": "FDA PDUFA Sept 19 - Opzelura pediatric expansion"
    },
    {
      "symbol": "CBRL",
      "approved": true,
      "consensus_score": 7.08,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5.5,
        "risk": 6.5
      },
      "position_size_pct": 4,
      "position_size_shares": 80,
      "current_price": 50.91,
      "stop_price": 46.84,
      "target_price": 60,
      "catalyst": "Q4 Earnings Sept 17 AMC - short squeeze setup (34% SI)"
    },
    {
      "symbol": "PASG",
      "approved": false,
      "consensus_score": 6.28,
      "agent_scores": {
        "fundamental": 6.5,
        "technical": 5.8,
        "news": 7.0,
        "sentiment": 6,
        "bull": 6.8,
        "bear": 6,
        "risk": 5
      },
      "position_size_pct": 2,
      "position_size_shares": 284,
      "current_price": 7.22,
      "stop_price": 5.78,
      "target_price": 10,
      "catalyst": "Insider buying + Q4 clinical data FTD gene therapy"
    },
    {
      "symbol": "RIVN",
      "approved": true,
      "consensus_score": 7.88,
      "agent_scores": {
        "fundamental": 8.5,
        "technical": 7.8,
        "news": 9.0,
        "sentiment": 8,
        "bull": 8.8,
        "bear": 5,
        "risk": 8
      },
      "position_size_pct": 5,
      "position_size_shares": 358,
      "current_price": 14.33,
      "stop_price": 12.54,
      "target_price": 15,
      "catalyst": "Q3 deliveries early October - peak quarter expected"
    }
  ],
  "executed": [],
  "rejected": [
    "SRRK",
    "INCY",
    "CBRL",
    "PASG",
    "RIVN"
  ]
}